Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research note ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Valneva (NASDAQ:VALN – Free Report) had its price target cut by HC Wainwright from $19.00 to $18.00 in a report released on Thursday,Benzinga reports. They currently have a buy rating on the stock. HC ...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics. The French pharma company ...